Cell and Gene Therapy Third-Party Logistics Market Outlook 2026-2034: Market Share, and Growth Analysis By Type (Clinical, Commercial), By Product (Cell Therapies, Gene Therapies), By Temperature Range, By Therapeutic Area, By End-User

The Cell and Gene Therapy Third-Party Logistics Market is valued at USD 10.46 billion in 2025 and is projected to grow at a CAGR of 11.6% to reach USD 28.09 billion by 2034. Cell and Gene Therapy ... もっと見る

出版社	出版年月	電子版価格	納期	言語
OG Analysis オージーアナリシス	2025年11月11日	US$3,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	通常3-4営業日以内	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

Table of Contents

Summary

The Cell and Gene Therapy Third-Party Logistics Market is valued at USD 10.46 billion in 2025 and is projected to grow at a CAGR of 11.6% to reach USD 28.09 billion by 2034.

Cell and Gene Therapy Third-Party Logistics Market

The Cell & Gene Therapy (CGT) Third-Party Logistics market orchestrates vein-to-vein movement of highly sensitive autologous and allogeneic products - from patient or donor collection, through manufacturing, to clinical sites and home-based administration. Unlike conventional cold chain, CGT logistics must maintain chain-of-identity and chain-of-custody at every handoff while operating across multiple temperature bands (cryogenic vapor, deep-frozen, frozen, and controlled-cold/CRT). Providers blend certified packaging, validated lanes, control-tower visibility, and white-glove couriers with GMP/GDP-aligned quality systems, clinical site readiness, and round-the-clock exception management. Growth is propelled by expanding trial pipelines, accelerated approvals, and the push to decentralize care; at the same time, network complexity, customs and biospecimen permits, airport tarmac risks, and capacity limits for cryo shippers and storage hubs raise execution risk. Differentiation hinges on end-to-end orchestration - slot scheduling, apheresis coordination, manufacturing window alignment - as well as digital traceability that fuses telemetry, e-sign chain-of-identity, and integrations to EMR/LIMS/MES and scheduling platforms. As off-the-shelf allogeneic modalities scale, providers are building regional cryogenic depots, standardizing release testing handoffs, and expanding direct-to-patient and at-home infusion models under strict nursing and pharmacovigilance protocols. Sustainability is entering specifications via reusable shippers, optimized routing, and carbon reporting without compromising thermal or compliance buffers. Ultimately, buyers select partners on validated performance under stress (weather, customs, strikes), documented audit readiness, and the ability to replicate outcomes across countries and sites - turning logistics from a cost center into a clinical-risk control function that safeguards every dose.

Cell and Gene Therapy Third-Party Logistics Market Key Insights

• Vein-to-vein orchestration is the core value Best-in-class 3PLs don’t just move parcels; they synchronize apheresis, manufacturing slots, QC release, and site infusion windows. Control-tower teams manage exceptions in real time, escalate to medical affairs when needed, and document every intervention to preserve product integrity and patient timelines.
• Autologous vs. allogeneic dictates network design Autologous therapies require individualized, just-in-time lanes with zero substitution and strict chain-of-identity, often using cryogenic vapor shippers and white-glove couriers. Allogeneic products behave more like biologics at scale, shifting demand toward regional cryo storage, batch release coordination, and multi-site replenishment models.
• Cryogenic infrastructure is a competitive moat Capacity and proximity of validated LN₂ storage, refurbishment centers for vapor shippers, and rapid re-charge capabilities determine resilience. Providers invest in redundant freezers, shock/tilt/temperature telemetry, and validated cleaning to prevent cross-contamination while sustaining tight turnaround times.
• Digital traceability and data interoperability decide speed Serialized IDs, e-sign chain-of-identity, live sensor feeds, and APIs into EMR/LIMS/MES compress cycle time and reduce manual errors. Platforms that unify logistics with slot scheduling and batch status let sponsors anticipate delays and re-optimize routes before windows close.
• Quality systems must mirror GMP discipline GDP alone is insufficient; sponsors expect SOP harmonization across hubs, qualified personnel, deviation/CAPA rigor, change-control governance, and audit readiness aligned to clinical and commercial GxP expectations - down to shipper preconditioning records and lane re-qualification.
• Customs, permits, and bio-compliance are make-or-break Human-derived materials, dry ice, and data-logged devices trigger varied import/export permits and airline rules. Experienced 3PLs pre-clear documentation, maintain country playbooks, and stage contingency routes to avoid tarmac dwell, weekend holds, and freezer shortages at transit nodes.
• Site readiness and white-glove execution reduce variance Training infusion centers on receipt, storage, and thaw; validating last-meter transfers; and coordinating nursing schedules prevent on-site deviations. On-call field engineers and redundant couriers protect against elevator outages, access restrictions, and power events.
• Risk management shifts from reporting to prediction Weather, strikes, and airport congestion are modeled into dynamic ETAs and reroutes; telemetry thresholds trigger automated interventions. Sponsors demand post-journey analytics - time-out-of-environment, excursions, and root causes - to refine protocols and qualify alternates.
• Scalability needs standardized building blocks Modular SOPs, validated packaging families, replica hub layouts, and global training curricula let providers stand up new corridors quickly. Standard SKUs for shippers, sensors, and documentation reduce variability across studies and markets.
• Sustainability with proof, not promises Reusable shippers, optimized milk-runs, and carbon reporting enter RFP scoring, but cannot erode thermal safety or audit trails. Leaders publish methodologies, tie routing choices to measurable impact, and align sustainability with compliance and dose security.

Cell and Gene Therapy Third-Party Logistics Market Reginal Analysis

North America

A dense CGT pipeline, experienced sites, and established cryogenic networks make this the largest and most complex theater. Sponsors expect 24/7 control towers, redundant depots near manufacturing clusters, and tight integrations with hospital EMRs and apheresis schedulers. Airport choice, customs pre-clearance for cross-border lanes, and contingency stock at regional hubs are standard. Home-based and direct-to-patient pilots expand under strict nursing, safety, and data protocols.

Europe

Multi-country trials require mastery of tissue/cell directives, country-specific permits, and weekend airport operations. 3PLs build distributed cryo hubs to minimize cross-border exposure and tarmac risk, with documentation and multilingual SOPs central to audits. Hospital networks favor harmonized training and validated last-meter workflows; sponsors reward providers that convert complex import regimes into predictable, repeatable delivery windows.

Asia-Pacific

Rapid growth in manufacturing and clinical sites collides with diverse import rules, public-holiday cycles, and long haul corridors. Success depends on local language control towers, in-region cryo storage, and playbooks for airport handoffs in hot/humid climates. Japan, Australia, and select hubs offer mature pathways; emerging markets require hands-on permit support, site training, and conservative lane qualifications to protect first-in-country studies.

Middle East & Africa

Specialized centers and government initiatives are increasing, but cryogenic infrastructure and customs procedures vary widely. 3PLs win by staging regional depots, pre-validating airport transfers under extreme heat, and providing on-site training for receipt/thaw. Close collaboration with health authorities and redundancy on courier legs are essential to avoid weekend and holiday bottlenecks.

South & Central America

Growth is anchored in major metros with capable hospitals and labs, while secondary cities need capacity building. Import licensing, dry-ice handling, and limited cold-room access at airports create dwell risks; leading 3PLs pre-stage shippers, use escorted transfers, and maintain bilingual documentation. Sponsors prioritize partners who can standardize SOPs across diverse regulatory environments while safeguarding chain-of-identity end to end.

Cell and Gene Therapy Third-Party Logistics Market Segmentation

By Type

Clinical

Commercial

By Product

Cell Therapies

Gene Therapies

By Temperature Range

Ambient Storage

Refrigerated Storage

Ultra-Low Temperature Storage

Cryogenic Storage

By Therapeutic Area

Oncology

Neurology

Cardiovascular Diseases

Ophthalmology

Infectious Diseases

Others

By End-User

Biopharmaceutical Companies

CDMOs/CMOs

Others

Key Market players

Cryoport Systems, Marken (UPS), World Courier (Cencora), DHL Supply Chain (Life Sciences & Healthcare), UPS Healthcare, FedEx Custom Critical, Kuehne+Nagel, Biocair, Yourway, MNX Global Logistics, PCI Pharma Services, Fisher Clinical Services (Thermo Fisher Scientific), Almac Clinical Services, Catalent Clinical Supply Services, GEODIS, CEVA Logistics, DSV, Yusen Logistics, Nippon Express (NX) Pharma Logistics, Airspace

Cell and Gene Therapy Third-Party Logistics Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends. Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Cell and Gene Therapy Third-Party Logistics Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis’ proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption. Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Cell and Gene Therapy Third-Party Logistics market data and outlook to 2034
- United States
- Canada
- Mexico
Europe — Cell and Gene Therapy Third-Party Logistics market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- BeNeLux
- Russia
- Sweden
Asia-Pacific — Cell and Gene Therapy Third-Party Logistics market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
Middle East and Africa — Cell and Gene Therapy Third-Party Logistics market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
South and Central America — Cell and Gene Therapy Third-Party Logistics market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru

* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the Cell and Gene Therapy Third-Party Logistics value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Cell and Gene Therapy Third-Party Logistics industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Cell and Gene Therapy Third-Party Logistics Market Report

Global Cell and Gene Therapy Third-Party Logistics market size and growth projections (CAGR), 2024-2034
Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Cell and Gene Therapy Third-Party Logistics trade, costs, and supply chains
Cell and Gene Therapy Third-Party Logistics market size, share, and outlook across 5 regions and 27 countries, 2023-2034
Cell and Gene Therapy Third-Party Logistics market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
Short- and long-term Cell and Gene Therapy Third-Party Logistics market trends, drivers, restraints, and opportunities
Porter’s Five Forces analysis, technological developments, and Cell and Gene Therapy Third-Party Logistics supply chain analysis
Cell and Gene Therapy Third-Party Logistics trade analysis, Cell and Gene Therapy Third-Party Logistics market price analysis, and Cell and Gene Therapy Third-Party Logistics supply/demand dynamics
Profiles of 5 leading companies—overview, key strategies, financials, and products
Latest Cell and Gene Therapy Third-Party Logistics market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
Complimentary report update to incorporate the latest available data and the impact of recent market developments.

* The updated report will be delivered within 3 working days"

ページTOPに戻る

1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Global Cell and Gene Therapy Third-Party Logistics Market Summary, 2025
2.1 Cell and Gene Therapy Third-Party Logistics Industry Overview
2.1.1 Global Cell and Gene Therapy Third-Party Logistics Market Revenues (In US$ billion)
2.2 Cell and Gene Therapy Third-Party Logistics Market Scope
2.3 Research Methodology

3. Cell and Gene Therapy Third-Party Logistics Market Insights, 2024-2034
3.1 Cell and Gene Therapy Third-Party Logistics Market Drivers
3.2 Cell and Gene Therapy Third-Party Logistics Market Restraints
3.3 Cell and Gene Therapy Third-Party Logistics Market Opportunities
3.4 Cell and Gene Therapy Third-Party Logistics Market Challenges
3.5 Tariff Impact on Global Cell and Gene Therapy Third-Party Logistics Supply Chain Patterns

4. Cell and Gene Therapy Third-Party Logistics Market Analytics
4.1 Cell and Gene Therapy Third-Party Logistics Market Size and Share, Key Products, 2025 Vs 2034
4.2 Cell and Gene Therapy Third-Party Logistics Market Size and Share, Dominant Applications, 2025 Vs 2034
4.3 Cell and Gene Therapy Third-Party Logistics Market Size and Share, Leading End Uses, 2025 Vs 2034
4.4 Cell and Gene Therapy Third-Party Logistics Market Size and Share, High Growth Countries, 2025 Vs 2034
4.5 Five Forces Analysis for Global Cell and Gene Therapy Third-Party Logistics Market
4.5.1 Cell and Gene Therapy Third-Party Logistics Industry Attractiveness Index, 2025
4.5.2 Cell and Gene Therapy Third-Party Logistics Supplier Intelligence
4.5.3 Cell and Gene Therapy Third-Party Logistics Buyer Intelligence
4.5.4 Cell and Gene Therapy Third-Party Logistics Competition Intelligence
4.5.5 Cell and Gene Therapy Third-Party Logistics Product Alternatives and Substitutes Intelligence
4.5.6 Cell and Gene Therapy Third-Party Logistics Market Entry Intelligence

5. Global Cell and Gene Therapy Third-Party Logistics Market Statistics – Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2034
5.1 World Cell and Gene Therapy Third-Party Logistics Market Size, Potential and Growth Outlook, 2024- 2034 ($ billion)
5.1 Global Cell and Gene Therapy Third-Party Logistics Sales Outlook and CAGR Growth By Type, 2024- 2034 ($ billion)
5.2 Global Cell and Gene Therapy Third-Party Logistics Sales Outlook and CAGR Growth By Product, 2024- 2034 ($ billion)
5.3 Global Cell and Gene Therapy Third-Party Logistics Sales Outlook and CAGR Growth By Temperature Range, 2024- 2034 ($ billion)
5.4 Global Cell and Gene Therapy Third-Party Logistics Sales Outlook and CAGR Growth By Therapeutic Area, 2024- 2034 ($ billion)
5.5 Global Cell and Gene Therapy Third-Party Logistics Sales Outlook and CAGR Growth By End-User, 2024- 2034 ($ billion)
5.6 Global Cell and Gene Therapy Third-Party Logistics Market Sales Outlook and Growth by Region, 2024- 2034 ($ billion)

6. Asia Pacific Cell and Gene Therapy Third-Party Logistics Industry Statistics – Market Size, Share, Competition and Outlook
6.1 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Insights, 2025
6.2 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast By Type, 2024- 2034 (USD billion)
6.3 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast By Product, 2024- 2034 (USD billion)
6.4 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast By Temperature Range, 2024- 2034 (USD billion)
6.5 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast By Therapeutic Area, 2024- 2034 (USD billion)
6.6 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast By End-User, 2024- 2034 (USD billion)
6.7 Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Revenue Forecast by Country, 2024- 2034 (USD billion)
6.7.1 China Cell and Gene Therapy Third-Party Logistics Market Size, Opportunities, Growth 2024- 2034
6.7.2 India Cell and Gene Therapy Third-Party Logistics Market Size, Opportunities, Growth 2024- 2034
6.7.3 Japan Cell and Gene Therapy Third-Party Logistics Market Size, Opportunities, Growth 2024- 2034
6.7.4 Australia Cell and Gene Therapy Third-Party Logistics Market Size, Opportunities, Growth 2024- 2034

7. Europe Cell and Gene Therapy Third-Party Logistics Market Data, Penetration, and Business Prospects to 2034
7.1 Europe Cell and Gene Therapy Third-Party Logistics Market Key Findings, 2025
7.2 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown By Type, 2024- 2034 (USD billion)
7.3 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown By Product, 2024- 2034 (USD billion)
7.4 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown By Temperature Range, 2024- 2034 (USD billion)
7.5 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown By Therapeutic Area, 2024- 2034 (USD billion)
7.6 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown By End-User, 2024- 2034 (USD billion)
7.7 Europe Cell and Gene Therapy Third-Party Logistics Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)
7.7.1 Germany Cell and Gene Therapy Third-Party Logistics Market Size, Trends, Growth Outlook to 2034
7.7.2 United Kingdom Cell and Gene Therapy Third-Party Logistics Market Size, Trends, Growth Outlook to 2034
7.7.2 France Cell and Gene Therapy Third-Party Logistics Market Size, Trends, Growth Outlook to 2034
7.7.2 Italy Cell and Gene Therapy Third-Party Logistics Market Size, Trends, Growth Outlook to 2034
7.7.2 Spain Cell and Gene Therapy Third-Party Logistics Market Size, Trends, Growth Outlook to 2034

8. North America Cell and Gene Therapy Third-Party Logistics Market Size, Growth Trends, and Future Prospects to 2034
8.1 North America Snapshot, 2025
8.2 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook By Type, 2024- 2034 ($ billion)
8.3 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook By Product, 2024- 2034 ($ billion)
8.4 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook By Temperature Range, 2024- 2034 ($ billion)
8.5 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook By Therapeutic Area, 2024- 2034 ($ billion)
8.6 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook By End-User, 2024- 2034 ($ billion)
8.7 North America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook by Country, 2024- 2034 ($ billion)
8.7.1 United States Cell and Gene Therapy Third-Party Logistics Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.7.1 Canada Cell and Gene Therapy Third-Party Logistics Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.7.1 Mexico Cell and Gene Therapy Third-Party Logistics Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. South and Central America Cell and Gene Therapy Third-Party Logistics Market Drivers, Challenges, and Future Prospects
9.1 Latin America Cell and Gene Therapy Third-Party Logistics Market Data, 2025
9.2 Latin America Cell and Gene Therapy Third-Party Logistics Market Future By Type, 2024- 2034 ($ billion)
9.3 Latin America Cell and Gene Therapy Third-Party Logistics Market Future By Product, 2024- 2034 ($ billion)
9.4 Latin America Cell and Gene Therapy Third-Party Logistics Market Future By Temperature Range, 2024- 2034 ($ billion)
9.5 Latin America Cell and Gene Therapy Third-Party Logistics Market Future By Therapeutic Area, 2024- 2034 ($ billion)
9.6 Latin America Cell and Gene Therapy Third-Party Logistics Market Future By End-User, 2024- 2034 ($ billion)
9.7 Latin America Cell and Gene Therapy Third-Party Logistics Market Future by Country, 2024- 2034 ($ billion)
9.7.1 Brazil Cell and Gene Therapy Third-Party Logistics Market Size, Share and Opportunities to 2034
9.7.2 Argentina Cell and Gene Therapy Third-Party Logistics Market Size, Share and Opportunities to 2034

10. Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Outlook and Growth Prospects
10.1 Middle East Africa Overview, 2025
10.2 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics By Type, 2024- 2034 (USD billion)
10.3 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics By Product, 2024- 2034 (USD billion)
10.4 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics By Temperature Range, 2024- 2034 (USD billion)
10.5 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics By Therapeutic Area, 2024- 2034 (USD billion)
10.6 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics By End-User, 2024- 2034 (USD billion)
10.7 Middle East Africa Cell and Gene Therapy Third-Party Logistics Market Statistics by Country, 2024- 2034 (USD billion)
10.7.1 Middle East Cell and Gene Therapy Third-Party Logistics Market Value, Trends, Growth Forecasts to 2034
10.7.2 Africa Cell and Gene Therapy Third-Party Logistics Market Value, Trends, Growth Forecasts to 2034

11. Cell and Gene Therapy Third-Party Logistics Market Structure and Competitive Landscape
11.1 Key Companies in Cell and Gene Therapy Third-Party Logistics Industry
11.2 Cell and Gene Therapy Third-Party Logistics Business Overview
11.3 Cell and Gene Therapy Third-Party Logistics Product Portfolio Analysis
11.4 Financial Analysis
11.5 SWOT Analysis

12 Appendix
12.1 Global Cell and Gene Therapy Third-Party Logistics Market Volume (Tons)
12.1 Global Cell and Gene Therapy Third-Party Logistics Trade and Price Analysis
12.2 Cell and Gene Therapy Third-Party Logistics Parent Market and Other Relevant Analysis
12.3 Publisher Expertise
12.2 Cell and Gene Therapy Third-Party Logistics Industry Report Sources and Methodology

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

OG Analysis社のヘルスケア・医薬品分野での最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート

よくあるご質問

OG Analysis社はどのような調査会社ですか?

OG Analysisは、10年以上の専門知識を持ち、半導体、エネルギー、化学品、自動車、農業など多様な市場調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。